Protalix BioTherapeutics, Inc. (PLX:NYSEMKT) closed at $2.72 on October 15, 2026, up 4.21% on the day. The stock trades 14.7% below its 52-week high of $3.19 and 70.0% above its 52-week low of $1.60. Over the past year, it gained 4.8%. Protalix BioTherapeutics, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -6.12% | -1.88% | +9.66% | +14.98% | +4.82% |
In 252 trading sessions since October 14, 2025, PLX closed higher on 123 days (49%). Its best day was October 20, 2025 (+15.05%) and its worst was October 17, 2025 (-22.50%). The stock moved 10% or more in a single session 6 times.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in Phase III clinical trial to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 that is in Phase II clinical trial to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.
Find more stocks like PLX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.